MiMedx Group Announces First Quarter Results

Share this story with your network

MARIETTA, Ga., April 27, 2010 /PRNewswire via COMTEX/ — MiMedx Group, Inc.(MDXG 1.49, +0.14, +10.37%) announced today its financial results for the first quarter ended March 31, 2010.

The Company recorded its first significant revenues during the quarter ended March 31, 2010. First quarter of 2010 revenues were $114,900, compared to no revenues reported for the first quarter of 2009. The Company reported a net loss from operations of $2.6M, which represents an 11% improvement as compared to the same period in 2009. This improvement also includes an incremental investment of $273,009 for sales & marketing expense related to building the Company’s global sales distribution network and extensive sales training program. The net loss for the first quarter of 2010 was $3.1M, or $.06 per diluted common share, which includes a non-cash interest expense charge of $499,610 for the unamortized discount on the conversion of the 3% Convertible Senior Secured Notes into common stock as of March 31, 2010. In 2009, the net loss was $2.9M for the first quarter, or $0.07 per diluted common share. Earnings before interest, taxes, depreciation and amortization (EBITDA)* were a loss of $2.3M for the first quarter of 2010, compared to a loss of $2.6M reported in the first quarter of 2009. Total long term debt decreased $3.0M as compared to December 31, 2009, as a result of the aforementioned conversion of notes payable to common stock. Stockholder’s equity as of March 31, 2010, was $7.4M as compared to $6.1M as of December 31, 2010.

The Company’s first quarter revenues and net loss were in line with expectations and the Company’s business plan. The results included the impact of production ramp-up and product launch costs for the HydroFix(TM) Vaso Shield and Spine Shield products, as well as planned investments in animal studies that were undertaken to facilitate FDA clearance of several new products. During the quarter, the Company also closed its Tampa-based administrative offices and consolidated all accounting and investor relations functions into its Marietta, Georgia headquarters.

Parker H. “Pete” Petit, Chairman and CEO, stated, “We are pleased with our first quarter results, especially in the development of our first significant revenues in the United States and internationally. During the quarter, we initiated the “soft launch” of our HydroFix(TM) Vaso Shield in the United States and our HydroFix(TM) Spine Shield internationally. Both products contributed to our first quarter revenues.

We were also pleased with the progress we made during the quarter in reducing our manufacturing costs. We successfully implemented reductions in the costs of manufacturing our HydroFix(TM) Vaso Shield and Spine Shield, and also made good progress in our preproduction environment by reducing costs for our collagen fiber. Since both of these products are expected to have high gross profit margins as sales develop, we are optimistic about the positive profit impact these cost reductions will have in future periods. ”

The Company also reported its progress in signing contractual agreements with numerous sales representative organizations in the United States and in identifying a number of foreign distributors that have a high level of interest in marketing the Company’s products. William C. “Bill” Taylor, President and COO said, “We have been able to attract quality rep groups in the U.S. because they see the opportunity with our currently available HydroFix(TM) products and our soon to be available CollaFix(TM) products that are manufactured from our collagen fibers. In the international market, the distributors are enthusiastic about our HydroFix(TM) Spine Shield product line.”

The Company further reported that it has offered holders of certain of its warrants to convert their warrants into common stock, on or before May 1, 2010, at a discounted cash exercise price. Petit added, “At this time, our expectations are that we will raise approximately $4 million through this offer.”

“We are encouraged relative to the progress of our business, and we believe we are off to a good start in 2010. We look forward to communicating our results throughout the year,” concluded Petit.

MiMedx management will host a live broadcast of its first quarter conference call on April 27, 2010, beginning at 10:30 a.m. Eastern Time. A listen-only simulcast of the MiMedx Group conference call will be available online at the Company’s website atwww.mimedx.com or at www.earnings.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company’s website at www.mimedx.com or at www.earnings.com.

* Earnings before interest, depreciation and amortization is a non-GAAP financial measure and should not be considered a replacement for GAAP results. For a reconciliation of this non-GAAP financial measure to the most directly comparable financial measure, see accompanying table to this release.

About MiMedx Group, Inc.

MiMedx Group, Inc. is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and is in the process of transitioning from a development-focused concern to an operating company focused on sales growth and profitability. The Company’s assets include intellectual property protecting its CollaFix(TM) collagen-based technology for augmentation of soft and connective tissue diseases and trauma and intellectual property protecting HydroFix(TM), a novel durable hydrogel technology. The Company has received FDA clearance for HydroFix(TM) Vaso Shield, which is indicated for use as a cover for vessels following anterior spinal surgery, and European clearance (CE Mark) for its HydroFix(TM) Spine Shield, which is indicated for use as an adhesion barrier for anterior spinal surgery. More information about MiMedx Group can be found at www.mimedx.com.

Safe Harbor Statement

This press release includes statements that look forward in time or that express management’s beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the expected gross profit margins on the Company’s products and the positive impact of cost reductions in future periods, the interest level of foreign distributors in the Company’s products, the timing of the availability of the Company’s CollaFix(TM) products, the amount of money that will be raised from the discount offer to certain warrant holders, and that first quarter activities and results are indicative of future performance. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the Company currently requires additional capital to survive and achieve its goals, which may be difficult or impossible to obtain through the discount offer to certain warrant holders or otherwise, that the Company may not receive requisite regulatory clearances and/or approvals to be able to market a full range of products or that such clearances or approvals may be delayed, that cost reductions may not be sustained or be sufficient to enable the Company to achieve profitability, that the Company may not be able to establish an effective distribution system for its products in the U.S. or abroad, that the Company’s products may not gain the anticipated acceptance in the marketplace or that acceptance may be delayed, and the risk factors detailed from time to time in the Company’s periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2009. By making these forward-looking statements, MiMedx Group does not undertake to update them in any manner except as may be required by the Company’s disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

                             MIMEDX GROUP, INC. AND SUBSIDIARIES
                              (A DEVELOPMENT STAGE ENTERPRISE)
                       CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                         (Unaudited)

                                                         Period from
                                                          Inception
                                                       (November 22,
                              Three Months Ended                        2006)
                                   March 31,              through
                                   ---------
                                   2010          2009  March 31, 2010
                                   ----          ----  --------------

    REVENUES:
          Net Sales            $114,855            $-         $114,855

    OPERATING
     COSTS AND
     EXPENSES:
          Cost of
           products
           sold                 379,588             -          379,588
          Research
           and
           development
           expenses             572,404       957,084        9,312,239
          Acquired
           in-
           process
           research
           and
           development                -             -      7,177,000
          Selling,
           General &
           Administrative
           expenses           1,711,157     1,915,594       22,355,164
          (Gain)/loss
           on sale of
           assets                     -             -         (275,428)
                                    ---           ---         --------

    LOSS FROM
     OPERATIONS              (2,548,294)   (2,872,678)     (38,833,708)

    OTHER
     INCOME
     (EXPENSE),
     net
          Financing
           expense
           associated
           with
           issuance
           of common
              stock for
               registration
               rights
               waivers                -             -       (1,305,100)
          Financing
           expense
           associated
           with
           warrants
           issued
              in
               connection
               with
               convertible
               promissory
               note            (568,636)            -     (1,544,469)
          Net
           interest
           (expense)
           income,
           net                  (25,155)          694        345,215
          Change in
           fair value
           of
           investment,
             related
              party                   -             -          (41,775)
                                    ---           ---          -------

    LOSS BEFORE
     INCOME
     TAXES                   (3,142,085)   (2,871,984)     (41,379,837)
          Income
           taxes                      -             -                -
                                    ---           ---              ---

    NET LOSS                 (3,142,085)   (2,871,984)     (41,379,837)
                             ----------    ----------      -----------

    Accretion
     of
     redeemable
     common
     stock and
           common
            stock with
            registration
            rights
           to fair
            value                     -             -       (2,158,823)
                                    ---           ---       ----------

    Loss
     attributable
     to common
     shareholders           $(3,142,085)  $(2,871,984)    $(43,538,660)
                            ===========   ===========     ============

    Net loss
     per common
     share
            Basic and
             diluted             $(0.06)       $(0.07)
                                 ======        ======

    Shares used
     in
     computing
     net loss
     per common
     share
            Basic and
             diluted         51,227,540    38,549,350
                             ==========    ==========

                       MIMEDX GROUP, INC. AND SUBSIDIARIES
                         (A DEVELOPMENT STAGE ENTERPRISE)
                      CONDENSED CONSOLIDATED BALANCE SHEETS

                                      ASSETS

                                                     March 31,
                                                                   December
                                                            2010      31,
                                                    (unaudited)          2009
                                                    -----------          ----
    Current assets:
        Cash and cash equivalents                     $1,627,505   $2,653,537
        Trade Accounts Receivable                        115,655
        Inventory                                         68,276       30,920
        Prepaid expenses and other current
         assets                                          171,854      121,277
                                                         -------      -------

            Total current assets                       1,983,290    2,805,734

    Property and equipment,
        net of accumulated depreciation of $1,059,438
         (March)
        and $948,445 (December)                          954,260    1,049,597
    Goodwill                                             857,597      857,597
    Intangible assets, net of accumulated
     amortization of $1,631,657 (March)
         and $1,464,674 (December)                     4,430,343    4,597,326
    Deferred financing costs                                   -      192,627
    Deposits and Other Long Term
     Receivables                                         111,180      189,202
                                                         -------      -------

            Total assets                              $8,336,670   $9,692,083
                                                      ==========   ==========

                        LIABILITIES AND STOCKHOLDERS' EQUITY

    Current liabilities:
        Accounts payable and accrued
         expenses                                       $928,050     $629,349

        Total current liabilities                        928,050      629,349

    Long term convertible debt, face value
     $3,472,000, less unamortized
     discount of $550,748 and including
      accrued interest of $69,604
      (December)                                               -    2,990,856
                                                             ---    ---------

            Total liabilities                            928,050    3,620,205
                                                         -------    ---------

    Commitments and contingency (Notes
     4 and 8)                                                  -            -

    Stockholders' equity:
        Preferred stock; $.001 par value; 5,000,000
         shares authorized and 0 (March and December)
          shares
         issued and outstanding                                -            -
        Common stock; $.001  par value; 100,000,000
         shares authorized and 58,500,083 (March) and
          50,002,887 (December)
         shares issued and outstanding                    58,550       50,003
        Additional paid-in capital                    50,924,762   46,454,482
        Treasury stock (50,000 shares at
         cost)                                           (25,000)     (25,000)
        Deficit accumulated during the
         development stage                           (43,549,692) (40,407,607)
                                                     -----------  -----------

            Total stockholders' equity                 7,408,620    6,071,878
                                                       ---------    ---------

            Total liabilities and stockholders'
             equity                                   $8,336,670   $9,692,083
                                                      ==========   ==========

                          MIMEDX GROUP, INC. AND SUBSIDIARIES
                            (A DEVELOPMENT STAGE ENTERPRISE)
                     Non-GAAP Financial Measures and Reconciliation

    As used herein, "GAAP" refers to generally accepted accounting
    principles in the United States. We use various numerical measures
    in conference calls, investor meetings and other forums which are or
    may be considered "Non-GAAP financial Measures" under Regulation G.
    We have Provided below for your reference supplemental financial
    disclosure for these measures, including the most directly
    comparable GAAP measure and an associated reconciliation.

    Reconciliation of Net Loss to Earnings before Interest, Depreciation
    & Amortization (EBITDA)

                                           Three Months Ended
                                                March 31,
                                                ---------

                                           2010                  2009
                                           ----                  ----

     Net Loss (Per GAAP)            $(3,142,085)          $(2,871,984)

     Add back:
     Income Taxes                             -                     -

     Financing expense assoc. with
      warrants issued in connection
      with  convertible promissory
      note                             (568,636)                    -

     Net interest (exp)/inc., net       (25,155)                 (694)

     Depreciation Expense               110,992               111,820
     Amortization Expense               166,983               166,704

     EBITDA                         $(2,270,319)          $(2,594,154)
                                    ===========           ===========

SOURCE MiMedx Group, Inc.

Leave a Comment

Your email address will not be published. Required fields are marked *

*